行情

REGN

REGN

再生元制药
NASDAQ

实时行情|Nasdaq Last Sale

295.87
+9.72
+3.40%
盘后: 295.87 0 0.00% 18:25 09/20 EDT
开盘
288.75
昨收
286.15
最高
297.64
最低
286.68
成交量
170.17万
成交额
--
52周最高
442.00
52周最低
271.57
市值
324.96亿
市盈率(TTM)
17.00
分时
5日
1月
3月
1年
5年

分析师评级

20位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

REGN 新闻

  • fitbit暴跌500%后暴涨12% 谷歌会接盘以此对抗苹果吗
  • 钛媒体.1天前
  • 美联储政策制定者似乎对今年再次降息持开放态度
  • 新浪美股.1天前
  • 巴克莱:人造肉公司Beyond Meat的前方是星辰和大海
  • 新浪财经综合.1天前
  • 黑石英国策略曝光,资本之王怎么看脱欧?
  • 新浪财经-自媒体综合.1天前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

REGN 简况

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
展开

Webull提供Regeneron Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。